DEVELOPMENT OF ANTHRAX VACCINE FORMULATI0N

该项目的主要目标是支持候选产品的先进开发，这些产品由疫苗成分与技术成分（干燥配方技术）相结合组成，以提高稳定性并最大限度地减少冷链或防腐剂的要求，以便在故意释放或应对由NIAID a、B和C类优先病原体引起的自然发生的传染病暴发后的事件环境中使用。

The primary objective of this project is to support the advanced development of candidate products which consist of a vaccine component in combination with a technology component (a dry formulation technology) to increase stability and minimize cold chain or preservative requirements for use in post-event settings following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens.